肿瘤防治研究2023年第50卷第1期CancerResPrevTreat,2023,Vol.50,No.1·43·doi:10.3971/j.issn.1000-8578.2023.22.0495·临床研究·基于CiteSpace的肺癌免疫治疗研究的可视化分析杨淑燕1，庄金满1，刘宇航1，朱金秀2，林梦心3，何斐1VisualAnalysisofResearchonLungCancerImmunotherapybyUsingCiteSpaceYANGShuyan1,ZHUANGJinman1,LIUYuhang1,ZHUJinxiu2,LINMengxin3,HEFei11.DepartmentofEpidemiologyandBiostatistics,SchoolofPublicHealth,FujianMedicalUniversity,Fuzhou350122,China;2.DepartmentofRespiratoryMedicine,FuzhouPulmonaryHospital,Fuzhou350008,China;3.DepartmentofOncology,UnionHospitalofFujianMedicalUniversity,Fuzhou350001,ChinaCorrespondingAuthor:HEFei,E-mail:i.fei.he@fjmu.edu.cnAbstract:ObjectiveTounderstandthecurrentstatusofresearchonlungcancerimmunotherapytoprovideareferenceforfurtherinvestigationandfuturetopicselectioninthisfield.MethodsCiteSpacevisualizationanalysissoftwarewasusedtoanalyze400ChinesestudiesinCNKIand5001EnglishstudiesintheWebofSciencedatabasefrom2005to2021,with“lungcancer”and“immunotherapy”askeywords.Keywordco-occurrenceanalysiswasperformedon17Englishstudiesof“LungCancer”“Immunotherapy”and“Singlecellsequencing”intheWebofSciencedatabase.Results“Non-smallcelllungcancer”“immunosuppressants”“PD-L1”“dendriticcells”and“cytokine-inducedkillercells”arecurrentresearchhotspotsinlungcancerimmunotherapy.Monoclonalantibodydrugsincludingnivolumab,pembrolizumab,atezolizumab,anddurvalumabarehotspotdrugs.ImmunotherapycombinedwithchemotherapyaswellasPD-L1expressionhavebecomethefocusofcontinuousresearch.ThemajorityofstudiesonlungcancerimmunotherapyareconductedintheUnitedStates,followedbyChina.ConclusionLungcancerimmunotherapyhasgraduallybecomearesearchhotspotinChina.Inthefuture,in-depthresearchisneededtoprovidecutting-edgedirectionsforlungcancerimmunotherapy.Keywords:Lungcancer;Immunotherapy;Singlecellsequencing;Visualanalysis;CiteSpaceFunding:MedicalInnovationProjectofFujianHealthResearchTalentsTrainingProject(No.2019-CX-33);FujianScienceandTechnologyInnovationJoin...
